MacroGenics Announces Publication of SOPHIA Trial Results for MARGENZA™ in JAMA Oncology
January 25, 2021 07:30 ET
|
MacroGenics, Inc.
Primary endpoint of Phase 3 study met with MARGENZA (margetuximab-cmkb) showing a 24% Progression Free Survival (PFS) relative risk reduction compared to Herceptin® (trastuzumab), both with...